DETERMINING HUMAN ERYTHROCYTE SENSITIVITY TO LYSIS WITH COMPLEMENT SYSTEM ACTIVATION ON THROMBIN PATHWAY Russian patent published in 2019 - IPC G01N31/00 

FIELD: immunology.

SUBSTANCE: invention refers to clinical immunology and haemostasiology and concerns determining human erythrocyte sensitivity to lysis with complement system activation on thrombin pathway. For ohuman erythrocytes sensitivity to lysis is evaluated when the complement system is activated on a thrombin path using citrate plasma with high thrombin activity associated with fibrin. To inhibit complement activation by one of the known three routes (classical, alternative or lectin), sodium citrate is used as a chelator for binding Ca²⁺ and Mg²⁺. In the presence of high thrombin activity associated with fibrin, component C5 is activated and a membrane-attack complex is formed, which is determined by lysis of human erythrocytes. Degree of HE lysis is determined from a calibration curve, where 100 % lysis is complete lysis of human erythrocytes with water addition, and erythrocyte control for spontaneous lysis – 0 % lysis. Parallel is determined by the standard HE blood group technique. Most sensitive to lysis are human erythrocytes with blood group A, second place HE with blood group AB, in third place HE with blood group B. Most stable are human erythrocytes with 0 blood group.

EFFECT: this test can be used for personified prediction of severity of reperfusion syndrome with complement activation by thrombin pathway of complement system, as well as for selection of treatment approach in given pathological situations.

1 cl, 2 dwg, 4 tbl